Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TNYA Tenaya Therapeutics Inc

Market Closed 12-12 16:00:00 EST

0.8500

-0.5100

-37.50%

盘后0.8690

+0.0190+2.24%

19:59 EST

High1.05	Low0.7850	Vol66.59M
Open1.05	D1 Closing1.36	Amplitude19.49%
Mkt Cap141.53M	Tradable Cap129.62M	Total Shares166.51M
T/O58.09M	T/O Rate43.67%	Tradable Shares152.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TNYA","market":"US","secType":"STK","nameCN":"Tenaya Therapeutics Inc","latestPrice":0.85,"timestamp":1765573200000,"preClose":1.36,"halted":0,"volume":66591396,"hourTrading":{"tag":"盘后","latestPrice":0.869,"preClose":0.85,"latestTime":"19:59 EST","volume":163003,"amount":138113.91095,"timestamp":1765587579276},"delay":0,"floatShares":152496722,"shares":166505885,"eps":-0.720885,"marketStatus":"Market Closed","change":-0.51,"latestTime":"12-12 16:00:00 EST","open":1.05,"high":1.05,"low":0.785,"amount":58088134.2114324,"amplitude":0.194853,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.720885,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":1.36,"preHourTrading":{"tag":"盘前","latestPrice":1.04,"preClose":1.36,"latestTime":"09:29 EST","volume":1014743,"amount":1096525.2988163,"timestamp":1765549795141},"postHourTrading":{"tag":"盘后","latestPrice":0.869,"preClose":0.85,"latestTime":"19:59 EST","volume":163003,"amount":138113.91095,"timestamp":1765587579276},"volumeRatio":38.3227189883099,"impliedVol":1.1962,"impliedVolPercentile":0.34},"requestUrl":"/m/hq/s/TNYA/tweets","defaultTab":"tweets","newsList":[{"id":"2591658591","title":"Tenaya Therapeutics (TNYA) Is Down 39.7% After FDA Lifts TN-201 Hold and Trial Updates - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2591658591","media":"Simply Wall St.","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591658591?lang=en_us&edition=fundamental","pubTime":"2025-12-13 23:35","pubTimestamp":1765640158,"startTime":"0","endTime":"0","summary":"Earlier this month, Tenaya Therapeutics reported that the FDA lifted the clinical hold on its MyPEAK-1 Phase 1b/2a trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and released encouraging interim Phase 1b/2 data for TN-401 in arrhythmogenic right ventricular cardiomyopathy, while also completing a US$60,000,000 composite units offering.\nTogether, the resumed TN-201 trial and early TN-401 signals highlight Tenaya’s push to use AAV9-based gene therapies to address inherited...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-tnya-is-down-397-after-fda-lifts-tn-201","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-tnya-is-down-397-after-fda-lifts-tn-201","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0},{"id":"2591468687","title":"Tenaya Stock Plunges After $60 Million Equity Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2591468687","media":"Benzinga_recent_news","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591468687?lang=en_us&edition=fundamental","pubTime":"2025-12-13 02:56","pubTimestamp":1765565760,"startTime":"0","endTime":"0","summary":"Heart disease-focused Tenaya Therapeutics falls on high volume after pricing a $60 million offering and releasing new TN-401 data, while the FDA clears the TN-201 trial hold.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/12/Stock-Market-Remains-Largely-Unfazed-Wit.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/12/Stock-Market-Remains-Largely-Unfazed-Wit.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49371243/tenaya-stock-plunges-after-60-million-equity-offering","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49371243/tenaya-stock-plunges-after-60-million-equity-offering","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["ACM","BK4139","LU2238339852.HKD","BK4129","LU0187121727.USD","BK4585","BK4539","LU0689626769.HKD","BK4588","LU1861214812.USD","EQR","LU2298064838.USD","BK4215","BK4516","LU1939255532.USD","TNYA","LU2360107325.USD","LU0124676726.USD","LU1861219969.SGD","LU2308191902.HKD","LU2244417387.USD"],"gpt_icon":0},{"id":"2590501725","title":"Tenaya Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $3 From $5","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501725","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501725?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:48","pubTimestamp":1765547301,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nAZN4RDLMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TNYA","BK4139","BK4539"],"gpt_icon":0},{"id":"2590501850","title":"Tenaya Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501850","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501850?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:20","pubTimestamp":1765545600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TNYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 08:20 ET (13:20 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA"],"gpt_icon":0},{"id":"2590527558","title":"Tenaya Therapeutics Announces Pricing of Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590527558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590527558?lang=en_us&edition=fundamental","pubTime":"2025-12-12 13:16","pubTimestamp":1765516613,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA4LQTPC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","TNYA"],"gpt_icon":0},{"id":"2590544071","title":"BUZZ-Tenaya Therapeutics slides after launching stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590544071","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590544071?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:25","pubTimestamp":1765491937,"startTime":"0","endTime":"0","summary":"BUZZ-Tenaya Therapeutics slides after launching stock offering** Drug developer Tenaya Therapeutics' TNYA.O shares slide 12.5% to $1.19 in extended trading** TNYA unveils public offering of common stock and warrants; size not disclosed** Leerink Partners and Piper Sandler are joint bookrunning managers for offering ** Separately, TNYA announces data from early trial for experimental gene therapy in rare heart condition** TNYA has 166.5 million outstanding shares for $233 million market cap, per LSEG data** All eight brokerages covering the stock rate it \"buy\" or higher; median PT $5 - data compiled by LSEG** As of last close, TNYA stock down 4.9% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL6N3XH135:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNSH","TNYA","BK4139","BK4539","BK4127","PIPR","BK4207"],"gpt_icon":0},{"id":"2590491445","title":"BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2590491445","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590491445?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:05","pubTimestamp":1765487138,"startTime":"0","endTime":"0","summary":"BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition Dec 11 (Reuters) - Tenaya Therapeutics Inc TNYA.O:TENAYA THERAPEUTICS REPORTS POSITIVE INTERIM DATA FR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA542KXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TNYA","BK4139"],"gpt_icon":0},{"id":"2590454151","title":"Tenaya Therapeutics Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590454151","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590454151?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:02","pubTimestamp":1765486920,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Dec.  11, 2025  (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204290/0/en/Tenaya-Therapeutics-Announces-Proposed-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HCM","BK4585","BK4139","BK4588","BK4531","TNYA","BK4539"],"gpt_icon":0},{"id":"2590354996","title":"FDA Lifts Clinical Hold on Tenaya Therapeutics’ MyPEAK-1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590354996","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590354996?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486878,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc. has announced that the U.S. Food and Drug Administration  has lifted the clinical hold on its MyPEAK-1 Phase 1b/2a clinical trial of TN-201, a gene therapy being developed for the treatment of MYBPC3-associated hypertrophic cardiomyopathy. The decision follows Tenaya's successful resolution of all FDA concerns related to the hold. The company is now implementing protocol amendments agreed upon with the FDA and plans to resume dosing in collaboration with clinical sites. No new safety issues have been identified, and Tenaya does not expect the hold to affect its data milestones or development timelines.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL4T58RL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","LU2095319765.USD","BK4139","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","TNYA","LU2210150020.SGD","SG9999014013.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","BK4112","BK4539","SG9999014005.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2590499515","title":"Tenaya Therapeutics Reports Positive Interim Results for TN-401 Gene Therapy in ARVC Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590499515","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590499515?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486876,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc. announced positive interim results from Cohort 1 of the ongoing RIDGE-1 Phase 1b/2 clinical trial evaluating TN-401 gene therapy for adults with PKP2-associated arrhythmogenic right ventricular cardiomyopathy . According to the company, TN-401 was well tolerated at the 3E13 vg/kg dose, with robust gene transduction and increased PKP2 protein levels observed in the first two patients at week 8. Clinically meaningful reductions in arrhythmia burden were reported in the first two patients with more than six months of follow-up. Tenaya Therapeutics plans to present these preliminary results during a webcast conference call on December 11, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL1vHmXV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","TNYA","BK4585","SG9999014005.SGD","LU2095319765.USD","BK4139","BK4539","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","IE00BKPKM429.USD","BK4588","LU2210150020.SGD","NDAQ","BK4112","IE00B64PRP62.GBP","SG9999014021.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2590935549","title":"Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for Mypeak-1™ Phase 1B/2a Clinical Trial of Tn-201 Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590935549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590935549?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA3JPBFL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","TNYA"],"gpt_icon":0},{"id":"2590154991","title":"Tenaya Therapeutics Inc - Does Not Expect Hold to Impact Data Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2590154991","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590154991?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA3JPBFL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","TNYA"],"gpt_icon":0},{"id":"2590603549","title":"Tenaya Therapeutics Inc - Tn-401 Well Tolerated at 3E13 Vg/Kg Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2590603549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590603549?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA542KXW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0},{"id":"2590549679","title":"Tenaya Therapeutics Inc: Robust Transduction and Demonstrated Increases in Pkp2 Protein Levels in First Two Patients at Week 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2590549679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590549679?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA542KXW:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TNYA","BK4139","BK4539"],"gpt_icon":0},{"id":"2590496785","title":"Tenaya Therapeutics Inc - Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients With More Than Six Months of Follow-up","url":"https://stock-news.laohu8.com/highlight/detail?id=2590496785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590496785?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA542KXW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","TNYA"],"gpt_icon":0},{"id":"2590415455","title":"Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC","url":"https://stock-news.laohu8.com/highlight/detail?id=2590415455","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590415455?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":"TN-401 was Well Tolerated at 3E13 vg/kg doseRobust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8Clinically Meaningful Reductions in Arrhythmia Burden O","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204284/0/en/Tenaya-Therapeutics-Reports-Positive-Interim-Data-from-Cohort-1-of-RIDGE-1-Phase-1b-2-Clinical-Trial-of-TN-401-Gene-Therapy-for-Adults-with-PKP2-associated-ARVC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA","HCM","BK4539","ACM","LU0689626769.HKD","LU0187121727.USD","LU2360107325.USD","LU2308191902.HKD","BK4531","LU1861214812.USD","LU2238339852.HKD","BK4585","BK4139","BK4007","BK4516","BK4588","LU2298064838.USD","BK4129","LU1861219969.SGD","LU0124676726.USD","LU2244417387.USD","LU1939255532.USD"],"gpt_icon":0},{"id":"2584358921","title":"Tenaya Therapeutics Inc - FDA Places Clinical Hold On Tenaya's Mypeak-1 Trial - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584358921","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584358921?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:07","pubTimestamp":1763572056,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc ::*TENAYA THERAPEUTICS INC - FDA PLACES CLINICAL HOLD ON TENAYA'S MYPEAK-1 TRIAL - SEC FILING*TENAYA THERAPEUTICS INC - EXPECTS NO IMPACT ON TN-201 TIMELINES FROM HOLD - SEC FI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD19b9Pz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TNYA","BK4139"],"gpt_icon":0},{"id":"2583565567","title":"LifeSci Capital Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583565567","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583565567?lang=en_us&edition=fundamental","pubTime":"2025-11-15 23:35","pubTimestamp":1763220924,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Cory Jubinville, PhD reiterated a Buy rating on Tenaya Therapeutics today and set a price target of $3.00. According to Tip...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-reaffirms-their-buy-rating-on-tenaya-therapeutics-tnya-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-reaffirms-their-buy-rating-on-tenaya-therapeutics-tnya-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNYA"],"gpt_icon":0},{"id":"2582627366","title":"Tenaya Therapeutics (TNYA) Receives a Buy from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2582627366","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582627366?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:18","pubTimestamp":1762863505,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Michael Ulz maintained a Buy rating on Tenaya Therapeutics yesterday and set a price target of $5.00. The company’s shares c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/tenaya-therapeutics-tnya-receives-a-buy-from-morgan-stanley-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/tenaya-therapeutics-tnya-receives-a-buy-from-morgan-stanley-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4516","LU0912757837.SGD","LU2111349929.HKD","LU0795875169.SGD","LU1244550577.SGD","BK4539","LU1989772923.USD","LU0971096721.USD","LU1244550221.USD","LU1363072403.SGD","LU2347655156.SGD","LU0882574139.USD","LU1244550494.USD","LU1162221912.USD","BK4588","IE00BZ1G4Q59.USD","BK4139","LU0098860793.USD","LU0267386448.USD","IE00BKVL7J92.USD","LU2023251221.USD","LU0320765646.SGD","LU1732800096.USD","LU0106261372.USD","LU0158827781.USD","LU1074936037.SGD","LU1720051108.HKD","LU2028103732.USD","LU1720051017.SGD","TNYA","BK4127","LU1989772840.SGD","LU2089284900.SGD","LU1732799900.SGD","LU0158827948.USD","BK4504","LU2271345857.HKD","LU1548497426.USD","LU1668664300.SGD","LU0557290698.USD","LU0795875086.SGD","LU0106831901.USD","LU2357305700.SGD","BK4534","LU0006306889.USD","LU0225283273.USD","LU2133065610.SGD","LU2089283258.USD","LU0234570918.USD","BK4585"],"gpt_icon":0},{"id":"2582356117","title":"Chardan Capital Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582356117","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582356117?lang=en_us&edition=fundamental","pubTime":"2025-11-11 16:15","pubTimestamp":1762848955,"startTime":"0","endTime":"0","summary":"Chardan Capital analyst Geulah Livshits maintained a Buy rating on Tenaya Therapeutics yesterday and set a price target of $9.00. The company’s sha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-reaffirms-their-buy-rating-on-tenaya-therapeutics-tnya-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-reaffirms-their-buy-rating-on-tenaya-therapeutics-tnya-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNYA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tenayatherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.3972},{"period":"1month","weight":-0.4481},{"period":"3month","weight":-0.2917},{"period":"6month","weight":0.437},{"period":"1year","weight":-0.6909},{"period":"ytd","weight":-0.4056}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.092404},{"month":2,"riseRate":0.25,"avgChangeRate":0.060915},{"month":3,"riseRate":0.25,"avgChangeRate":-0.154481},{"month":4,"riseRate":0.25,"avgChangeRate":0.087213},{"month":5,"riseRate":0.25,"avgChangeRate":-0.005732},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069846},{"month":7,"riseRate":0.5,"avgChangeRate":-0.023292},{"month":8,"riseRate":0.4,"avgChangeRate":0.09529},{"month":9,"riseRate":0.4,"avgChangeRate":-0.101393},{"month":10,"riseRate":0.2,"avgChangeRate":-0.046678},{"month":11,"riseRate":0.4,"avgChangeRate":0.123533},{"month":12,"riseRate":0.2,"avgChangeRate":-0.109205}],"exchange":"NASDAQ","name":"Tenaya Therapeutics Inc","nameEN":"Tenaya Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tenaya Therapeutics Inc(TNYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tenaya Therapeutics Inc,TNYA,Tenaya Therapeutics Inc股票,Tenaya Therapeutics Inc股票老虎,Tenaya Therapeutics Inc股票老虎国际,Tenaya Therapeutics Inc行情,Tenaya Therapeutics Inc股票行情,Tenaya Therapeutics Inc股价,Tenaya Therapeutics Inc股市,Tenaya Therapeutics Inc股票价格,Tenaya Therapeutics Inc股票交易,Tenaya Therapeutics Inc股票购买,Tenaya Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tenaya Therapeutics Inc(TNYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction